Please login to the form below
MaxCyte
This page shows the latest MaxCyte news and features for those working in and with pharma, biotech and healthcare.
MaxCyte gets green light for solid tumour cell therapy
MaxCyte has two sides to its business, developing its own therapies on one hand and on the other licensing its flow electroporation platform for use by other companies. ... MaxCyte’s approach could mean that its therapies are quicker and easier to
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Maxcyte, a global cell- based therapies and life sciences company that is developing its CARMA process, where a patient’s peripheral blood mononuclear cells (PBMCs) are removed and
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
